Brand drug nam­ing faces chal­lenges in emerg­ing cat­e­gories, ex­pert says

As brand drug nam­ing gets more dif­fi­cult, some ther­a­py ar­eas like obe­si­ty and Alzheimer’s dis­ease are fac­ing even more chal­lenges. That’s be­cause both are tra­di­tion­al­ly …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER